Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26914912 | 0.87 | MEN1 (0.39) | MEN1KMT2APTPN1HDAC8NAMPT | |
| SCHEMBL29264412 | 0.80 | MEN1 (0.33) | MEN1KMT2ANAMPT | |
| SCHEMBL26914887 | 0.76 | PTPN1 (0.53) | MEN1KMT2APTPN1NR1H2GPR119 | |
| SCHEMBL26914884 | 0.75 | PTPN1 (0.35) | MEN1KMT2APTPN1NR1H2GPR119 | |
| SCHEMBL26914879 | 0.74 | PTPN1 (0.43) | MEN1KMT2APTPN1NR1H2GPR119 | |
| SCHEMBL26914886 | 0.73 | PTPN1 (0.34) | MEN1KMT2APTPN1NR1H2GPR119 | |
| SCHEMBL26914874 | 0.72 | NR1H2 (0.39) | MEN1KMT2APTPN1NR1H2CNR2 | |
| SCHEMBL26091660 | 0.69 | NR1H2 (0.48) | NR1H2GPR119NAMPT | |
| SCHEMBL30685433 | 0.69 | MEN1 (0.39) | MEN1KMT2APTPN1HDAC8NAMPT | |
| SCHEMBL26914911 | 0.69 | MEN1 (0.39) | MEN1KMT2APTPN1HDAC8NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124443-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD (CN) | 2024-04-18 | — | — | US | disclosed |
| EP-4289850-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Scinnohub Pharmaceutical Co., Ltd (CN) | 2023-12-13 | — | — | EP | disclosed |
| EP-4289850-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Scinnohub Pharmaceutical Co., Ltd (CN) | 2023-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124443-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | F2, PLG, PLAT | MEN1 726/4885KMT2A 2898/4885PTPN1 3909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.